BACKGROUND: Obesity and its related illness is a primary health concern today. METHODS: Five hundred morbidly obese patients (mean age 42 years; mean preoperative weight 123 kg) underwent laparoscopic adjustable gastric banding surgery in a private U.S. hospital setting within a comprehensive multidisciplinary bariatric program. Patients were followed up to 36 months. Comorbidity status was assessed for 163 patients who completed > or =18 months' follow-up by comparing medications (type and dosage) prescribed for each comorbid condition before surgery and at follow-up. RESULTS: At 36 months after surgery, mean body mass index (BMI) had decreased from 45.2 to 34.9 kg/m(2) and mean percent excess weight loss (%EWL) was 47%. Complications were as follows: gastric pouch dilatation (6.8%), slippage (2.8%), and stoma obstruction (0.6%). There was no mortality. Resolution or improvement of comorbidities were as follows: gastroesophageal reflux disease (GERD) (87%; usually immediately postsurgery), asthma (81.8%), diabetes (66%), dyslipidemia (65.5%), hypertension (48%), and sleep apnea (33%). CONCLUSIONS: Gastric banding provides good weight loss and significant reduction in comorbidities with few and minor complications.
BACKGROUND:Obesity and its related illness is a primary health concern today. METHODS: Five hundred morbidly obesepatients (mean age 42 years; mean preoperative weight 123 kg) underwent laparoscopic adjustable gastric banding surgery in a private U.S. hospital setting within a comprehensive multidisciplinary bariatric program. Patients were followed up to 36 months. Comorbidity status was assessed for 163 patients who completed > or =18 months' follow-up by comparing medications (type and dosage) prescribed for each comorbid condition before surgery and at follow-up. RESULTS: At 36 months after surgery, mean body mass index (BMI) had decreased from 45.2 to 34.9 kg/m(2) and mean percent excess weight loss (%EWL) was 47%. Complications were as follows: gastric pouch dilatation (6.8%), slippage (2.8%), and stoma obstruction (0.6%). There was no mortality. Resolution or improvement of comorbidities were as follows: gastroesophageal reflux disease (GERD) (87%; usually immediately postsurgery), asthma (81.8%), diabetes (66%), dyslipidemia (65.5%), hypertension (48%), and sleep apnea (33%). CONCLUSIONS: Gastric banding provides good weight loss and significant reduction in comorbidities with few and minor complications.
Authors: Jonathan Zagzag; Bradley F Schwack; Heekoung Youn; Christine Ren Fielding; George A Fielding; Marina S Kurian Journal: Surg Endosc Date: 2011-09-23 Impact factor: 4.584
Authors: Rishi Singhal; Catherine Bryant; Mark Kitchen; Khalid S Khan; Jon Deeks; Boliang Guo; Paul Super Journal: Surg Endosc Date: 2010-07-31 Impact factor: 4.584
Authors: Wendy M Miller; Katherine E Nori-Janosz; Martin Lillystone; Jose Yanez; Peter A McCullough Journal: Curr Cardiol Rep Date: 2005-11 Impact factor: 2.931
Authors: M A Küper; K M Kramer; A Kirschniak; A Kischniak; M Zdichavsky; J H Schneider; D Stüker; T Kratt; A Königsrainer; F A Granderath Journal: Obes Surg Date: 2009-06-10 Impact factor: 4.129